mRNA-1083
mRNA-1083mRNAcombination flu + COVID-19 mRNA vaccine
Seasonal Influenza
Phase 3
1 program·1 trial·View drug →
No upcoming catalysts on file.
DashboardSell5,233$70.79−$370.5KSell46,441$65.60−$3.0MAward5,580$87.34$487.3KSell17,706$71.14−$1.3MAward3,246$65.76$213.4KBuy15,073$88.51+$1.3M HepatologyCo-Investigator$798.2K6GastroenterologyCo-Investigator$655.7K7GastroenterologyResearch Grant$594.0K6GastroenterologyCo-Investigator$569.5K5GastroenterologyCo-Investigator$536.2K4GastroenterologyResearch Grant$480.3K3GastroenterologyResearch Grant$457.7K6GastroenterologyResearch Grant$433.5K3HepatologyCo-Investigator$329.9K5GastroenterologyEquity / Ownership$283.0K6
MRNANASDAQ
Moderna
Moderna, Inc. · Cambridge, MA · founded 2010
Moderna is a Cambridge, Massachusetts biotech that designs and manufactures messenger RNA (mRNA) medicines. The platform encodes a target protein’s instructions in mRNA so that, once injected, the body’s own cells produce the protein — used most famously in the Spikevax COVID-19 vaccine and now extended to flu, RSV, combination respiratory vaccines, personalized cancer vaccines (with Merck), and several rare-disease programs.
- Lead asset
- mRNA-1083 · Ph3 · Seasonal Influenza
- mRNA · combination flu + COVID-19 mRNA vaccine
- Pipeline
- 2 drugs · 2 programs
- 2 Vaccines
- Modalities
- mRNA×2
FocusVaccinesOncology - SolidRare Disease
$44.00-20.83%1Y
MRNA · daily close · illustrative · 3 catalysts marked
P3 readout+32%Conf.+5%PDUFA+21%
1Y high$57.491Y low$43.22range$14.27(33%)past catalysts
Peers in this space
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase2programs
- Preclin0
- Ph10
- Ph20
- Ph32
- Filed0
- Approved0
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Apr 15, 2026ReadoutmRNA-1083 P304 Flu+COVID Phase 3 ToplinePositive+32.0%+43.9%+28.7%
Jan 25, 2026Conf.mRNA-1083 — ASH Late-Breaker — Updated SurvivalPositive+4.5%+9.8%+9.5%
Oct 27, 2025PDUFAmRNA-1647 — PDUFA — ApprovedMixed+21.2%-23.8%-42.7%
Dec 1, 2024InterimmRNA-1083 — Phase 3 Interim — Stopped for EfficacyPositive+12.9%+15.9%+23.9%
Jan 6, 2024Conf.mRNA-1083 — ASH Late-Breaker — Updated SurvivalMixed+4.1%-7.0%-4.5%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 6 transactions · 6 insiders
Net flow
−$3.3M
Buys
$1.3M
1 txns
Sells
$4.7M
3 txns
Largest
−$3.0M
CFO sell
Net flow per quarter · last 8Q
11 txns · sum −$6.63M
24Q325Q125Q326Q126Q2
buys · $1.33Msells · $7.96M
Insider · roleActionSharesPriceValueDate
D. Mendoza
CMO
Apr 24, 2026
S. Volkov
CFO
Apr 23, 2026
A. Morais
Director
Mar 12, 2026
R. Singh
Director
Mar 7, 2026
C. Morais
CSO
Feb 28, 2026
K. Park
EVP
Feb 22, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
4 trades · 3 members
Est. net flow
−$3.53M
midpoint · brackets only
Buys
0
Sells
4
Party mix
1 D3 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
D
Sell$1.00M–$5.00M~$3.00MselfSen. A. Reyes
Senate · CA
Apr 17, 2026
filed +14d
R
Sell$50K–$100K~$75KspouseRep. J. Calhoun
House · GA
Jan 26, 2026
filed +25d
R
Sell$250K–$500K~$375KselfRep. J. Calhoun
House · GA
Jan 11, 2026
filed +24d
R
Partial sell$50K–$100K~$75KspouseRep. N. Schaefer
House · WI
Sep 10, 2025
filed +25d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
7 ETFs hold the position
Held by ETFs
$131.7M
aggregate position
Of market cap
1.06%
aggregate ETF share
Top holder
XLV0.18%
Health Care Select Sector SPDR
TickerETF · familyThemeNAV% of NAVPosition
XLVBroad healthcare$39.00B0.18%$70.2M
Health Care Select Sector SPDR
SPDR
XBIBroad biotech$7.90B0.34%$26.9M
SPDR S&P Biotech ETF
SPDR
IBBBroad biotech$8.40B0.25%$21.0M
iShares Biotechnology ETF
iShares
ARKKInnovation$5.50B0.10%$5.5M
ARK Innovation ETF
ARK
IYHBroad healthcare$3.40B0.15%$5.1M
iShares U.S. Healthcare ETF
iShares
GNOMGenomics$90.0M3.06%$2.8M
Global X Genomics & Biotechnology
VanEck
PBEBroad biotech$175.0M0.19%$333K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
21 physicians paid · 90 disclosed records
Total 2025+2024
$6.35M
YoY
-34%
Research Grant$2.46MCo-Investigator$2.04MEquity / Ownership$1.37MConsulting$287.0KSpeaking$158.6KTravel & Lodging$30.0KFood & Beverage$1.8K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Lin Park
MD Anderson
Dr. Henry Nakamura
University of Washington
Dr. Henry Mendoza
Memorial Sloan Kettering
Dr. Devon Fischer
Johns Hopkins
Dr. Liam Romano
UCSF
Dr. Henry Mendoza
Yale Medical
Dr. Yuki Park
University of Washington
Dr. Rebecca Andersson
Cedars-Sinai
Dr. James Reyes
Cleveland Clinic
Dr. Theo Kowalski
Duke University
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$718K disclosed · 4 firms engaged
YoY change
+38%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Tiber Creek Group$279K
6 quarters active
Van Scoyoc Associates$173K
5 quarters active
Thorn Run Partners$150K
4 quarters active
K&L Gates$116K
2 quarters active
Top issues lobbied
- Rare Pediatric Disease Priority Review Voucher$226K
- Medicare Part B coverage for gene therapies$139K
- Sunshine Act expansion$87K
- BIOSIM Act / Biosimilars$75K
- CMS reimbursement rates for ultra-rare conditions$75K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
6 awards · 4 agencies
Total awarded
$430.7M
across all programs
Active
$410.3M
option periods incl.
Top agency
HHS$250.9M
largest active: Strategic National Stockpile — Therapeutic Procurement
AgencyTitle · type · award IDStatusValueAwarded → ends
CDCactive$10.7MApr 2026→ Aug 2029
Vaccine Adverse Event Surveillance
Contract · CDC-77107188
BARDAactive$146.3MApr 2026→ Oct 2027
Medical Countermeasure Stockpiling
Contract · BAR-75429238
HHSactive$250.9MMar 2026→ Dec 2028
Strategic National Stockpile — Therapeutic Procurement
Contract · HHS-20863779
CDCoption$1.1MMay 2025→ Oct 2026
Vaccine Adverse Event Surveillance
Contract · CDC-10159663
CDCoption$1.4MApr 2025→ Apr 2027
Vaccine Adverse Event Surveillance
Contract · CDC-80144605
NIH / NIAIDcompleted$20.4MFeb 2024→ Jan 2025
Vaccine Adjuvant Research — Phase 1 / 2
Grant · NIH-34160870
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
5 granted · 5 pending
Total in portfolio
10
Granted in last 12mo
2
Expiring < 2yr
0
Nearest expiry
Apr 2032
Patent #Title · inventor · drugTypeStatus · filedExpiry
10,245,061Composition of Matter
Genome editing constructs encoding mRNA-1647
S. Hoffman · mRNA-1647
grantedfiled Apr 2025
exp. Apr 2045
19.0y left
12,376,290Formulation
Sustained-release oral compositions of mRNA-1647
P. Schwartz + 4 · mRNA-1647
grantedfiled Apr 2024
exp. Apr 2044
18.0y left
US 2025/5697992 A1Method of Use
Combination therapy comprising mRNA-1647
P. Chen + 3 · mRNA-1647
pendingfiled Apr 2025
in prosecution
US 2022/3869814 A1Process
Recombinant production of therapeutic mRNA-1083
D. Schwartz + 1 · mRNA-1083
pendingfiled Apr 2022
in prosecution
10,972,459Method of Use
Pediatric methods of use for mRNA-1083
P. Voss + 3 · mRNA-1083
grantedfiled Apr 2017
exp. Apr 2037
11.0y left
US 2020/6865011 A1Composition of Matter
Antibody-drug conjugates with novel linkers for mRNA-1083
A. Goldstein · mRNA-1083
pendingfiled Apr 2020
in prosecution
10,463,228Formulation
Sustained-release oral compositions of mRNA-1083
M. Tanaka + 1 · mRNA-1083
grantedfiled Apr 2015
exp. Apr 2035
9.0y left
US 2018/8525133 A1Composition of Matter
Genome editing constructs encoding mRNA-1647
L. Goldstein + 3 · mRNA-1647
pendingfiled Apr 2018
in prosecution
showing 8 of 10 · full portfolio available on Pro
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
14 items from 5 categories
clinical6regulatory3corporate2earnings2partnership1
just now
MRNA announces interim analysis from mRNA-1647 pivotal study
Endpoints News$·clinical
2d ago
MRNA enters licensing agreement with major pharma for mRNA-1083
PR Newswire·partnership
4d ago
MRNA appoints new Chief Medical Officer
Business Wire·corporate
9d ago
MRNA provides quarterly cash position and operating runway update
Business Wire·earnings
18d ago
MRNA doses first patient in Phase 3 mRNA-1083 study
FierceBiotech·clinical
21d ago
MRNA completes enrollment in mRNA-1647 Phase 2 trial
Endpoints News$·clinical
24d ago
MRNA reports Q1 financial results and pipeline update
Business Wire·earnings
28d ago
MRNA doses first patient in Phase 3 mRNA-1083 study
Endpoints News$·clinical
1mo ago
MRNA appoints new Chief Medical Officer
Business Wire·corporate
1mo ago
MRNA presents mRNA-1083 data at major medical conference
FierceBiotech·clinical
2mo ago
MRNA receives Orphan Drug Designation for mRNA-1083
Endpoints News$·regulatory
2mo ago
FDA grants Fast Track Designation to MRNA's mRNA-1083 program
Endpoints News$·regulatory
2mo ago
MRNA doses first patient in Phase 3 mRNA-1647 study
FierceBiotech·clinical
3mo ago
EMA validates MRNA's Marketing Authorization Application for mRNA-1083
PR Newswire·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$44.00
Open
$44.22
Day Δ
-0.22
-0.50%
Day range
$43.76 – $44.46
52W range
$43.22 – $57.49
Avg daily volume
3.78M
Valuation & ownership
Enterprise value
$6.9B
Shares out
281.82M
Float
262.09M
Insider %
6.92%
Institutional %
56.92%
Beta
1.92
vs SPY · 52w
Balance sheet & burn
Cash + invest
$10.6B
Total debt
$831M
Debt / equity
7.92
Cash burn / Q
$569M
R&D spend TTM
$2.1B
20% of cash
ATM available
$2.1B
dilution risk
Earnings
EPS latest
$-0.07
EPS Δ vs prior
+0.12
EPS estimate
$-0.15
next quarter
EPS prior
$-0.19
Next earnings
May 20, 2026
Rev guidance
$87M